European Heart Journal Advance Access originally published online on April 18, 2006
European Heart Journal 2006 27(10):1230-1237; doi:10.1093/eurheartj/ehi878
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men
1 Research Institute of Public Health, University of Kuopio, P.O.Box 1627, 70211 Kuopio, Finland
2 Department of Internal Medicine, Kuopio University Hospital, Kuopio, Finland
3 Department of Physiology, University of Oulu, Oulu, Finland
4 Department of Pharmacology and Toxicology, Biocenter Oulu, University of Oulu, Oulu, Finland
5 Department of Public Health and General Practice, University of Kuopio, Kuopio, Finland
Received 15 August 2005; revised 20 February 2006; accepted 23 March 2006; online publish-ahead-of-print 18 April 2006.
* Corresponding author. Tel: +358 17 162950; fax: +358 17 162936. E-mail address: jariantero.laukkanen{at}uku.fi
Aims The prognostic significance of N-terminal pro-A-type (NT-proANP) and pro-B-type natriuretic peptides (NT-proBNP) is not well documented in population-based prospective studies. We, therefore, studied if both NT-proANP and NT-proBNP are predictive for overall death, cardiovascular events, and atrial fibrillation (AF) among middle-aged men without heart failure or AF at baseline.
Methods and results Plasma NT-proANP and NT-proBNP were measured in a representative population-based sample of 905 men (age 46–65 years) from eastern Finland. There were 110 deaths [58 cardiovascular and 40 coronary heart disease (CHD)] and 59 cases of AF during a follow-up of 10 years. The multivariable adjusted risk for overall was 1.35-fold (95% CI 1.15–1.57) and 1.52-fold (95% CI 1.21–1.91) for CHD death for each SD (160.8 pmol/L) increment in NT-proANP. The respective risks were 1.26-fold (95% CI 1.12–1.42) and 1.44-fold (95% CI 1.22–1.60) for each SD (58.9 pmol/L) increment in NT-proBNP. The adjusted risks for future AF were 1.46 (P<0.001) and 1.72-fold (P<0.001) for each SD increment in NT-proANP and NT-proBNP, respectively.
Conclusion The main finding of the present study is that NT-proANP and NT-proBNP are strong predictors of death from cardiovascular and other causes including AF. These natriuretic peptides add to the prognostic value of conventional risk factors and provide a non-invasive measure for identifying men with high risk of death and its co-morbidities.
Key Words: Atrial fibrillation • Coronary heart disease • Mortality • Natriuretic peptides • Population study
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Moertl, R. Berger, J. Struck, A. Gleiss, A. Hammer, N. G. Morgenthaler, A. Bergmann, M. Huelsmann, and R. Pacher Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1783 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Daniels, O. Ben-Yehuda, and A. S. Maisel Algorithms for Assessing Cardiovascular Risk in Women JAMA, July 11, 2007; 298(2): 177 - 177. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Struthers and C. Lang The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney Eur. Heart J., July 2, 2007; 28(14): 1678 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted Evid. Based Med., October 1, 2006; 11(5): 159 - 160. [Full Text] [PDF]
|
|